1. Гусев Е.И., Скворцова В.И., Стаховская Л.В. Эпидемиология инсульта в России. Журн. неврол. и психиатр. им. С.С.Корсакова, 2003; 8: 4–9.
2. Данилов А.Б., Давыдов О.С. Нейропатическая боль. М.: Боргес, 2007.
3. Рассеянный склероз и другие демиелинизирующие заболевания. Под ред. Е.И.Гусева, И.А.Завалишина, А.Н.Бойко М.: Миклош, 2004.
4. Торопина Г.Г., Егоров О.Е., Яхно Н.Н. Нейрофизиологические корреляты боли и чувствительных расстройств у больных сирингомиелией. Журн. неврол. и психиатр. им. С.С.Корсакова. 2004; 3.
5. Торопина Г.Г., Зенков Л.Р., Полушкина Н.Р., Яхно Н.Н. Центральная постинсультная боль: клинические и электрофизиологические характеристики. Неврол. журн. 2003; 4: 15–22.
6. Andersen G, Vestergaard K, Ingeman-Nielsen M, Jensen TS. Incidence of central post-stroke pain. Pain 1995; 61: 187–93.
7. Archibald CJ, McGrath PJ, Ritvo PG et al. Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain 1994; 58: 89–93.
8. Attal N, Bouhassira D. Central neuropathic pain. In: Pappagallo M, ed. The Neurological Basis of Pain. McGraw-Hill, New York, 2005; 301–19.
9. Backonja M, Serra J. Pharmacological management part 2: Lesserstudied neuropathic pain diseases. Pain Med, 2004; 5 (suppl. 1): 48–59.
10. Beiske AG, Pedersen ED, Czujko B, Myhr KM. Pain and sensory complaints in multiple sclerosis. Eur J Neurol 2004; 11: 479–82.
11. Boivie J, Leijon G, Johansson I. Central post-stroke pain – a study of the mechanisms through analyses of the sensory abnormalities. Pain 1989; 37: 173–85.
12. Boivie J. Central pain. In: MacMahon SB, Koltzenburg M (eds), Wall and Melzack's Textbook of Pain. Churchill Livingstone: Elsevier 2005; 1057–75.
13. Bowsher D. Allodynia in relation to lesion site in central post-stroke pain. J Pain 2005; 6 (11): 736–40.
14. Bowsher D. Central post-stroke («thalamic syndrome») and other central pains. Am J Hosp Palliat Care 1999; 16: 593–7.
15. Cardenas DD, Warms CA, Turner JA et al. Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial. Pain 2002; 96: 365–73.
16. Chen B, Stitik TP, Foye PM et al. Central post-stroke pain syndrome: yet another use for gabapentin? Am J Phys Med Rehab 2002; 81: 718–20.
17. Dinoff BL, Richards JS, Ness TJ. Use of topiramate for spinal cord injury-related pain. J Spinal Cord Med 2003; 26: 401–3.
18. Drewes AM, Andreasen A, Poulsen LH. Valproate for treatment of chronic central pain after spinal cord injury. A double-blind cross-over study. Paraplegia 1994; 32: 565–9.
19. Ducreux D, Attal N, Parker F, Bouhassira D. Mechanisms of central neuropathic pain: a combined psychophysical and fMRI study in syringomyelia.Brain. 2006; 12 (Pt 4): 63–76.
20. Erzurumlu A, Dursun H, Gunduz S. The management of chronic pain in spinal cord injured patients. The comparison of effectiveness of amitriptyline and carbamazepine combination and electroacupuncture application. J Rheumatol Med Rehabil 1996; 7: 176–80.
21. Espir ML, Millac P. Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol). J Neurol Neurosurg Psychiatry 1970; 33: 528–31.
22. Finnerup NB, Jensen TS. Spinal cord injury pain – mechanisms and treatment. Eur J Neurol 2004; 11: 73–82.
23. Finnerup NB, Sindrup SH, Bach FW et al. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain 2002; 96: 375–83.
24. Gamache FW Jr, Ducker TB. Syringomyelia: a neurological and surgical spectrum. J Spinal Disord 3; 2: 10–7.
25. Hansson PT, Lacerenza M, Marchettini P. Aspects of clinical and experimental neuropathic pain: the clinical perspective. In: Hansson PT, Fields HL, Hill RG, Marchettini P (eds) Neuropathic pain: pathophysiology and treatment. Progress in pain research and management, Vol 21. IASP Press, Seattle 2001; p. 1–18.
26. Hooge JP, Redekop WK. Trigeminal neuralgia in multiple sclerosis. Neurology 1995; 45: 1294–6.
27. Jensen TS, Rasmussen P, Reske-Nielsen E. Association of trigeminal neuralgia with multiple sclerosis: clinical and pathological features. Acta Neurol Scand 1982; 65: 182–9.
28. Lampl C, Yazdi K, Roper C. Amitriptyline in the prophylaxis of central post-stroke pain: preliminary results of 39 patients in a placebo-controlled, long-term study. Stroke 2002; 33: 3030–2.
29. Leandri M, Lundardi G, Inglese M et al. Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol 2000; 247: 556–8.
30. Leijon G, Boivie J. Central post-stroke pain – a controlled trial of amitriptyline and carbamazepine. Pain 1989; 36: 27–36.
31. Levendoglu F, Ogun CO, Ozerbil O et al. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine 2004; 29: 743–51.
32. Montero Homs J, Guttierez-Rivas E, Fernandez J, Navarro C. Epidemiological study of prevalence incidence and neuropathic pain characterization in neurology units. PREVADOL study. Neurologia 2005; 20 (8): 385–9.
33. Marchettini P, Formaglio F, Lacerenza M. Pain as heralding symptom in multiple sclerosis Neurol Sci 2006; 27: S294–6.
34. Milhorat TH, Kotzen RM, Mu HT et al. Dysesthetic pain in patients with syringomyelia. Neurosurgery 3: 40–7.
35. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis – Prevalence and clinical characteristics. Eur J Pain 2005; 9: 531–42.
36. Rog DJ, Nurmikko TJ, Friede T et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65: 812–9.
37. Sandford PR, Lindblom LB, Haddox JD. Amitriptyline and carbamazepine in the treatment of dysesthetic pain in spinal cord injury. Arch Phys Med Rehabil 1992; 73: 300–1.
38. Sekhon L, Fehlings M. Epidemiology, demographics, and pathophysiology of acute spinal cord injury. Spine 2001; 26: S2–12.
39. Siddall PJ, McClelland JM, Rutkowski SB, Cousins MJ. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain 2003; 103: 249–57.
40. Siddall PJ, Middleton JW. A proposed algorithm for the management of pain following spinal cord injury. Spinal Cord 2006; 44: 67–77.
41. Siddall PJ, Cousins MJ, Otte A et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006 28; 67 (10): 1792–800.
42. Solaro. Epidemiology and treatment of pain in multiple sclerosis subjects. Neurol Sci 2006; 27: S291–3.
43. Solaro C, Brichetto G, Amato MP et al., and the PaIMS Study Group. The prevalence of pain in multiple sclerosis. A multicenter cross-sectional study. Neurology 2004; 6: 919–21.
44. Solaro C, Lunardi GL, Capello E et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology 1998; 51: 609–11.
45. Solaro C, Uccelli MM, Guglieri P et al. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler 2000; 6: 192–3.
46. Svendsen KB, Jensen TS, Overvad K et al. Pain in patients with multiple sclerosis. Arch Neurol 2003; 60: 1089–94.
47. Svendsen KB, Jensen TS, Bach FW. The cannabinoid dronabinol reduces central pain in Multiple Sclerosis. A randomised double-blind placebo controlled cross-over trial. Bri Med J 2004; 329: 253–61.
48. Tai Q, Kirshblum S, Chen B et al. Gabapentin in the treatment ofneuropathic pain after spinal cord injury: a prospective, randomized, doubleblind, crossover trial. J Spinal Cord Med 2002; 25: 100–5.
49. To TP et al. Gabapentin for neuropathic pain following spinal cord injury. Spinal Cord 2002; 40: 282–5.
50. Torrance N, Smith B, Bennett M, Lee A. The Epidemiology of Chronic Pain of Predominantly Neuropathic Origin. Results From a General Population Survey The J Pain 2006; 7 (4): 281–9.
51. Vestergaard K, Andersen G, Gottrup H et al. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 2001; 56: 184–90.
52. Vranken JH et al. Pregabalin in patients with central neuropathic pain: A randomized, double-blind, placebo-controlled trial of a flexibledose regimen. Pain, 2007 Epub ahead.
53. Warnell P. The pain experience of a multiple sclerosis population: a descriptive study. Axone 1991; 13: 26–8.